# EDGAR Filing Document

**Accession Number:** 0001817713
**File Stem:** 0000950170-23-007323
**Filing Date:** 2023-3
**Character Count:** 18469
**Document Hash:** 237033d452dd1bbe624843867ea47311
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-007323.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0000950170-23-007323

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**EFFECTIVENESS DATE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Janux Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001817713
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 822289112
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270470
- **FILM NUMBER:** 23724371

**BUSINESS ADDRESS:**
- **STREET 1:** 10955 VISTA SORRENTO PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 751-4493

**MAIL ADDRESS:**
- **STREET 1:** 10955 VISTA SORRENTO PARKWAY
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**As filed with the Securities and Exchange Commission on March 10, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**Form S-8** 

**REGISTRATION STATEMENT** 

**UNDER** 

**THE SECURITIES ACT OF 1933** 

------

**Janux Therapeutics, Inc.** 

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **82-2289112** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(IRS employer**<br>**identification number)** |
| **10955 Vista Sorrento Parkway, Suite 200, San Diego, California** | **92130** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**2021 Equity Incentive Plan** 

**2021 Employee Stock Purchase Plan** 

**(Full titles of the plans)** 

**David Campbell, Ph.D.** 

**President and Chief Executive Officer** 

**Janux Therapeutics, Inc.** 

**10955 Vista Sorrento Parkway, Suite 200**

**San Diego, California 92130** 

**(858) 751-4493**

**(Name, address, including zip code and telephone number, including area code, of agent for service)** 

**Copies to:** 

**Kenneth J. Rollins, Esq.** 

**Edmond J. Lay, Esq.**

**Cooley LLP** 

**10265 Science Center Drive** 

**San Diego, California 92121** 

**(858) 550-6000** 

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☒ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒

------

**EXPLANATORY NOTE** 

The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,084,233 shares of common stock under the Janux Therapeutics, Inc. 2021 Equity Incentive Plan and an additional 416,846 shares of common stock under the Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan, pursuant to the provisions of each plan which provide for annual automatic increases in the number of shares of common stock reserved for issuance under each respective plan.

**INCORPORATION OF DOCUMENTS BY REFERENCE**

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.

The Registrant previously registered shares of common stock for issuance under its 2021 Equity Incentive Plan and its 2021 Employee Stock Purchase Plan under Registration Statements on Form S-8, filed with the Securities and Exchange Commission on [<u>June 11, 2021</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521188960/d170344ds8.htm) (File No. 333-257039) and [<u>March 18, 2022</u>](https://www.sec.gov/Archives/edgar/data/1817713/000095012322003537/janx_s-8_march_2022.htm) (File No. 333-263712).

Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.

**Item 8. Exhibits.** 

The exhibits to this Registration Statement are listed below:

---

| | |
|:---|:---|
| **Exhibit<br><u>Number</u>** | **<u>Exhibit Description</u>** |
| 4.1 | [<u>Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on June 15, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521191155/d177137dex31.htm) |
| 4.2 | [<u>Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed on June 15, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521191155/d177137dex32.htm) |
| 4.3 | [<u>Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-256297), as amended, filed on June 7, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521183568/d143369dex41.htm) |
| 5.1 | [<u>Opinion of Cooley LLP.</u>](janx-ex5_1.htm) |
| 23.1 | [<u>Consent of Independent Registered Public Accounting Firm.</u>](janx-ex23_1.htm) |
| 23.2 | [<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](janx-ex5_1.htm) |
| 24.1 | [<u>Power of Attorney (included on the signature page to this Registration Statement).</u>](#sig) |
| 99.1 | [<u>Janux Therapeutics, Inc. 2021 Equity Incentive Plan, and Forms of Option Grant Notice, Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 10.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-256297), as amended, filed on June 7, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521183568/d143369dex103.htm) |
| 99.2 | [<u>Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-256297), as amended, filed on June 7, 2021).</u>](https://www.sec.gov/Archives/edgar/data/0001817713/000119312521183568/d143369dex104.htm) |
| 107 | [<u>Filing Fee Table.</u>](janx-exfiling_fees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 10, 2023.

---

| | |
|:---|:---|
| **JANUX THERAPEUTICS, INC.** | **JANUX THERAPEUTICS, INC.** |
| By: | /s/ David Campbell, Ph.D. |
|  | David Campbell, Ph.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Campbell and Tighe Reardon, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ David Campbell, Ph.D. | President and Chief Executive Officer and Director | March 10, 2023 |
| David Campbell, Ph.D. | (Principal Executive Officer) |  |
| /s/ Tighe Reardon | Acting Chief Financial Officer  | March 10, 2023 |
| Tighe Reardon | (Principal Financial and Accounting Officer) |  |
| /s/ Jay Lichter, Ph.D. | Chairperson of the Board of Directors | March 10, 2023 |
| Jay Lichter, Ph.D. |  |  |
| /s/ Ron Barrett, Ph.D. | Director | March 10, 2023 |
| Ron Barrett, Ph.D. |  |  |
| /s/ Vickie Capps | Director  | March 10, 2023 |
| Vickie Capps |  |  |
| /s/ Sheila Gujrathi, M.D. | Director  | March 10, 2023 |
| Sheila Gujrathi, M.D. |  |  |
| /s/ Winston Kung | Director  | March 10, 2023 |
| Winston Kung |  |  |
| /s/ Alana McNulty | Director  | March 10, 2023 |
| Alana McNulty |  |  |
| /s/ Jake Simson, Ph.D. | Director  | March 10, 2023 |
| Jake Simson, Ph.D. |  |  |
| /s/ Peter Thompson, M.D. | Director  | March 10, 2023 |
| Peter Thompson, M.D. |  |  |

---

------

## Ex-5

![img151594875_0.jpg](img151594875_0.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;Kenneth J. Rollins+1 858 550 6136krollins@cooley.com

March 10, 2023

Janux Therapeutics, Inc.

10955 Vista Sorrento Parkway, Suite 200

San Diego, CA 92130

Ladies and Gentlemen:

You have requested our opinion, as counsel to Janux Therapeutics, Inc., a Delaware corporation (the "**Company**"), with respect to certain matters in connection with the filing by the Company of a Registration Statement on Form S-8 (the "**Registration Statement**") with the Securities and Exchange Commission (the "**Commission**") covering the offering of an aggregate of up to 2,501,079 shares of the Company's Common Stock, $0.001 par value per share (the "**Shares**"), including (i) 2,084,233 shares issuable pursuant to the Company's 2021 Equity Incentive Plan (the "**Incentive Plan**") and (ii) 416,846 shares issuable pursuant to the Company's 2021 Employee Stock Purchase Plan (together with the Incentive Plan, the "**Plans**").

In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectuses, the Plans, the Company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, and originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness and authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery, by all persons other than by the Company, of all documents where due authorization, execution and delivery are a prerequisite to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not sought independently to verify such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements under the Incentive Plan, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 10265 Science Center Drive San Diego, CA 92121<br>t: (858) 550-6000 f: (858) 550-6420 cooley.com

------

![img151594875_1.jpg](img151594875_1.jpg)

March 10, 2023

Page Two

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

By: <u>/s/ Kenneth J. Rollins</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kenneth J. Rollins

Cooley LLP 10265 Science Center Drive San Diego, CA 92121<br>t: (858) 550-6000 f: (858) 550-6420 cooley.com

------

## Ex-23

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan of Janux Therapeutics, Inc. of our report dated March 10, 2023, with respect to the financial statements of Janux Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

March 10, 2023

------

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**Janux Therapeutics, Inc.**

(Exact name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered(1)** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | &nbsp;&nbsp;Common Stock, par value $0.001 per share, Janux Therapeutics, Inc. 2021 Equity Incentive Plan | 457(c) and 457(h) | 2,084,233 shares(2) | $15.96(3) | $33264358.68(3) | 0.0001102 | $3665.73 |
| Equity | &nbsp;&nbsp;Common Stock, par value $0.001 per share, Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan | 457(c) and 457(h) | 416,846 shares(4) | $13.57(5) | $5656600.22(5) | 0.0001102 | $623.36 |
| **Total Offering Amounts** |  |  |  |  | **$38920958.90** |  | **$4289.09** |
| **Total Fee Offsets** |  |  |  |  |  |  | **—** |
| **Net Fee Due** |  |  |  |  |  |  | **$4289.09** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock ("**Common Stock**") that become issuable under the Janux Therapeutics, Inc. 2021 Equity Incentive Plan (the "**2021 Plan**") and the Janux Therapeutics, Inc. 2021 Employee Stock Purchase Plan (the "**2021 ESPP**") by reason of any stock dividend, stock split, recapitalization or any other similar transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Represents shares of Common Stock reserved for future grant under the 2021 Plan as a result of the automatic increase in shares reserved thereunder on January 1, 2023 pursuant to the terms of the 2021 Plan. The 2021 Plan provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2021 Plan on January 1st of each calendar year, from January 1, 2022 through January 1, 2031. The number of shares added each year will be equal to: (a) 5% of the total number of shares of capital stock of the Registrant outstanding on December 31st of the preceding calendar year; or (b) a lesser number of shares of Common Stock as the Registrant's board of directors (the **"Board"**) may designate no later than December 31st of the immediately preceding year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h). The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Common Stock as reported on The Nasdaq Global Market on March 8, 2023, a date within five business days prior to the filing of this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Represents additional shares of the Registrant's Common Stock reserved for issuance under the 2021 ESPP as a result of the automatic increase in shares reserved thereunder on January 1, 2023 pursuant to the terms of the 2021 ESPP. The 2021 ESPP provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2021 ESPP on January 1st of each calendar year, from January 1, 2022 through January 1, 2031. The number of shares of Common Stock added each year will be equal to the lesser of: (a) 1% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year; (b) 932,000 shares; or (c) such lesser number of shares of Common Stock as the Board may designate prior to the applicable January 1st.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h). The proposed maximum offering price per share and proposed maximum aggregate offering price are based on the average of the high and low sale prices of the Common Stock as reported on The Nasdaq Global Market on March 8, 2023, a date within five business days prior to the filing of this Registration Statement, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2021 ESPP.

------